<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04790422</url>
  </required_header>
  <id_info>
    <org_study_id>NL75824.041.20</org_study_id>
    <nct_id>NCT04790422</nct_id>
  </id_info>
  <brief_title>Nutrition to Relieve IBS Symptoms by Targeting the Microbiota</brief_title>
  <acronym>NUTRIMI</acronym>
  <official_title>Nutrition to Relieve IBS Symptoms by Targeting the Microbiota</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wageningen University and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministery of Economic affairs</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nexira</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wecare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roquette Freres</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ingredion Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ingredia S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Naturex</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Winclove</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bioiberica</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Darling Ingredients</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wageningen University and Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Irritable Bowel Syndrome (IBS) is functional gastrointestinal disorder that&#xD;
      affects a large number of people. To date, no adequate treatment is available. This is&#xD;
      partially due to the heterogeneity of the patients and the complicated pathology in which not&#xD;
      all mechanisms are understood.&#xD;
&#xD;
      Based on results of in vitro screening within the IBSQUtrition project, we selected promising&#xD;
      dietary supplements for validation of their potential beneficial effects on the microbiota of&#xD;
      IBS patients.&#xD;
&#xD;
      Objective: The primary objective is to determine the bifidogenic effects of a 4-week&#xD;
      intervention with one of four dietary supplements (Chondroitin sulfate, NOVELOSE® 3490, and&#xD;
      Pea Fiber, and Lactium®) in IBS patients. The secondary objective is to determine the effects&#xD;
      of the same intervention on fecal microbiota composition and SCFA concentration, IBS-related&#xD;
      complaints, Quality of Life, and stool frequency and consistency in IBS patients.&#xD;
&#xD;
      Study design: a double-blind, randomized, placebo-controlled trial with five parallel arms.&#xD;
      Study population: 70 adult (18-65 yrs) IBS patients Intervention: 4-week intervention period&#xD;
      with five parallel arms: 1) Chondroitin sulfate, 2) NOVELOSE® 3490, 3) Pea Fiber, 4)&#xD;
      Lactium®, and 5) Placebo supplement (Maltodextrin control), during which the study&#xD;
      participants consume the respective supplement twice per day.&#xD;
&#xD;
      Main study parameters/endpoints: The main study parameter is the (relative) abundance of&#xD;
      fecal Bifidobacterium. The secondary study parameters are fecal microbiota composition and&#xD;
      Short-Chain Fatty Acids (SCFAs) concentration, stool frequency and consistency, IBS-related&#xD;
      complaints, and Quality of Life (QoL).&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation, benefit and group&#xD;
      relatedness: Study participants have to invest about 7.4 hours of their time in this study&#xD;
      mainly to complete several questionnaires (short daily questionnaire, longer questionnaires&#xD;
      at two occasions), which is conveniently all possible from home. On two occasions they have&#xD;
      to collect stool (transported via courier to the research facility). They have to comply to&#xD;
      consume a commercially available supplement twice daily for four weeks. There are limited&#xD;
      risks for the study participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 11, 2021</start_date>
  <completion_date type="Actual">July 16, 2021</completion_date>
  <primary_completion_date type="Actual">July 16, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Abundance of feceal Bifidobacterium</measure>
    <time_frame>Change after the intervention of 4 weeks</time_frame>
    <description>Measured in fecal samples using 16S rRNA gene-based approaches</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>fecal microbiota composition</measure>
    <time_frame>Change after the intervention of 4 weeks</time_frame>
    <description>Measured in fecal samples using 16S rRNA gene-based approaches</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fecal microbiota metabolite levels</measure>
    <time_frame>Change after the intervention of 4 weeks</time_frame>
    <description>Measured in the fecal samples using HPLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool frequency</measure>
    <time_frame>daily during 4 weeks</time_frame>
    <description>Questions regarding how often participants defecate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool consistency</measure>
    <time_frame>daily during 4 weeks</time_frame>
    <description>Using the validated Bristol stool chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gastro-intestinal complaints</measure>
    <time_frame>daily during 4 weeks</time_frame>
    <description>Measured with a visual analog scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Irritable Bowel Syndrome severity</measure>
    <time_frame>4 weeks</time_frame>
    <description>measured using the validated IBS-SSS questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Irritable Bowel Syndrome related quality of life</measure>
    <time_frame>4 weeks</time_frame>
    <description>measured using the validated IBS-QoL questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mental wellbeing</measure>
    <time_frame>4 weeks</time_frame>
    <description>measuring using the validated hospital anxiety and despression score (HADS) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dietary intake</measure>
    <time_frame>4 weeks</time_frame>
    <description>Measured via a validated food frequency questionnaire (FFQ)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Dietary fiber 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dietary fiber 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>dietary fiber 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>caseine protein hydrolisate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Maltodextrine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary fiber supplement</intervention_name>
    <description>Dietary fiber</description>
    <arm_group_label>Dietary fiber 1</arm_group_label>
    <arm_group_label>Dietary fiber 2</arm_group_label>
    <arm_group_label>dietary fiber 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Caseine protein hydrolisate</intervention_name>
    <description>Dietary supplement</description>
    <arm_group_label>caseine protein hydrolisate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Maltrodextrine</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Maltodextrine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  IBS patients that meet the Rome IV criteria. This will be evaluated by the medical&#xD;
             supervisor;&#xD;
&#xD;
          -  Male and female adults, aged 18-65 years;&#xD;
&#xD;
          -  Having a Body Mass Index (BMI) between 18.5 and 30 kg/m2;&#xD;
&#xD;
          -  Willing to keep a stable dietary pattern throughout the study;&#xD;
&#xD;
          -  Having a smartphone to fill out the daily questionnaires.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Having a gastro-intestinal disease, such as celiac disease, Crohn's disease, or&#xD;
             Ulcerative colitis;&#xD;
&#xD;
          -  Having a history of intestinal surgery that might interfere with study outcomes. This&#xD;
             does not include an appendectomy or cholecystectomy;&#xD;
&#xD;
          -  Having a food allergy to milk protein or pulse protein;&#xD;
&#xD;
          -  Presence of significant systemic diseases, such as diabetes mellitus, cancer,&#xD;
             cardiovascular disease or respiratory disease;&#xD;
&#xD;
          -  When applicable: currently pregnant or breastfeeding, or intending to become pregnant&#xD;
             during the study, as this can affect stool patterns and wellbeing;&#xD;
&#xD;
          -  Use of antibiotic treatment less than 3 months before start of the study and no use of&#xD;
             antibiotics during the study;&#xD;
&#xD;
          -  Use of prebiotics and/or probiotics (should be stopped 4 weeks before the start of the&#xD;
             study) and infrequent use of other (fiber) supplements. Some supplements are allowed,&#xD;
             but intake should be kept stable during the whole study period (Supplements will be&#xD;
             judged by the medical supervisor MD Ben Witteman);&#xD;
&#xD;
          -  Currently following a FODMAP-restricted diet;&#xD;
&#xD;
          -  Use of medication that can interfere with the study outcomes, including anxiolytics,&#xD;
             proton pump inhibitors, laxatives (Over-the-counter laxatives are allowed, but intake&#xD;
             should be either stopped before the start of the study or kept stable during the&#xD;
             complete study period), and codeine, as judged by the medical supervisor MD Ben&#xD;
             Witteman;&#xD;
&#xD;
          -  Participation in another clinical trial at the same time;&#xD;
&#xD;
          -  Student or employee working at Food, Health and Consumer Research from Wageningen Food&#xD;
             and Biobased Research;&#xD;
&#xD;
          -  Alcohol intake ≥ 2 (women) or ≥ 4 (men) glasses of alcoholic beverages per day;&#xD;
&#xD;
          -  Abuse of illicit drugs;&#xD;
&#xD;
          -  Being incapacitated.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stichting Wageningen Research</name>
      <address>
        <city>Wageningen</city>
        <state>Gelderland</state>
        <zip>6708 WG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wageningen University and Research</investigator_affiliation>
    <investigator_full_name>Diederik Esser</investigator_full_name>
    <investigator_title>Project leader clinical trials</investigator_title>
  </responsible_party>
  <keyword>gut Microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

